Omega-3 Fatty Acids (EPA/DHA) के लिए Crohn's Disease
C साक्ष्य की तुलना करें छोटे अध्ययनों से सीमित साक्ष्य उपलब्ध हैं, लेकिन कुछ सकारात्मक संकेत मौजूद हैं।EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.
निष्कर्ष
EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.
Key Study Findings
जनसंख्या: DNBS-induced Crohn's disease BALB/c mouse model
जनसंख्या: IBD patients (review of nutritional interventions)
जनसंख्या: Vegan athletes (narrative review)
जनसंख्या: IBD patients (editorial commentary)
जनसंख्या: Crohn's disease patients
जनसंख्या: None
Key Statistics
6
अध्ययन
800
प्रतिभागी
Mixed
ग्रेड
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
सामान्य रूप से उपयोग की जाने वाली खुराकें
- general:
- 1,000-2,000 mg combined EPA/DHA per day
- ibdsupport:
- 2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)
अधिकतम सीमा: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
अनुसंधान में अध्ययन की गई खुराकें
| खुराक | अवधि | प्रभाव | N |
|---|---|---|---|
| 50, 100, and 200 mg/kg oral | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Neutral | -- |
| 95% | -- | Mixed | -- |
| None | -- | Mixed | 12194 |
| None | -- | Mixed | -- |
सेवन का सर्वोत्तम समय: With meals containing fat for better absorption
Safety & Side Effects
रिपोर्ट किए गए दुष्प्रभाव
- ⚠ Fishy aftertaste and burping
- ⚠ Mild gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Potential increased bleeding time at very high doses (>3 g/day)
- ⚠ May lower blood pressure slightly
ज्ञात अंतःक्रियाएँ
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
- ● Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)
सहनीय अधिकतम सेवन: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)
कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।
Frequently Asked Questions
Does Omega-3 Fatty Acids (EPA/DHA) help with Crohn's Disease?
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Crohn's Disease?
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Crohn's Disease?
Related Evidence
इसके लिए अन्य सामग्री Crohn's Disease
Omega-3 Fatty Acids (EPA/DHA) अन्य स्वास्थ्य स्थितियों के लिए
References
- [1] D Fetarayani et al.. Semergen. 2025. Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit. doi:10.1016/j.semerg.2025.102575 PubMed
- [2] Álvaro Vergara A Nieto et al.. Curr Nutr Rep. 2025. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review. doi:10.1007/s13668-025-00633-4 PubMed
- [3] Mohamed Sofiane Merakeb et al.. J Ethnopharmacol. 2025. Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. (flaxseed) in vivo. doi:10.1016/j.jep.2025.120001 PubMed
- [4] Kimsor Hong et al.. Autoimmun Rev. 2024. Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian randomization analysis. doi:10.1016/j.autrev.2024.103651 PubMed
- [5] Daniéla Oliveira Magro et al.. World J Gastroenterol. 2024. Interaction between diet and genetics in patients with inflammatory bowel disease. doi:10.3748/wjg.v30.i12.1644 PubMed
- [6] Xiaojing Jia et al.. Metabolites. 2023. Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: A Mediation Mendelian Randomization Study. doi:10.3390/metabo13101041 PubMed
- [7] Robert Carreras-Torres et al.. Sci Rep. 2020. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. doi:10.1038/s41598-020-76361-2 PubMed
- [8] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
- [9] Eleonora Scaioli et al.. Int J Mol Sci. 2017. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. doi:10.3390/ijms18122619 PubMed
- [10] Islam Khan et al.. Med Princ Pract. 2017. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. doi:10.1159/000468988 PubMed
- [11] Christian Lodberg Hvas et al.. Ugeskr Laeger. 2017. [Nutrition and dietary supplement in chronic inflammatory bowel diesease]. PubMed
- [12] Raquel Cristina Schwanke et al.. Eur J Pharmacol. 2016. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. doi:10.1016/j.ejphar.2015.08.050 PubMed
- [13] Alyssa Parian et al.. Curr Pharm Des. 2016. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. doi:10.2174/1381612822666151112145033 PubMed
- [14] Meagen McCusker et al.. Clin Dermatol. 2016. Nutrition and skin: Kids are not just little people. doi:10.1016/j.clindermatol.2016.07.004 PubMed
- [15] Raffi Lev-Tzion et al.. Cochrane Database Syst Rev. 2014. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub4 PubMed
- [16] S C Ng et al.. Aliment Pharmacol Ther. 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. doi:10.1111/apt.12464 PubMed
- [17] Eduard Cabré et al.. Br J Nutr. 2012. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. doi:10.1017/S0007114512001626 PubMed
- [18] Fiona J Bath-Hextall et al.. Cochrane Database Syst Rev. 2012. Dietary supplements for established atopic eczema. doi:10.1002/14651858.CD005205.pub3 PubMed
- [19] Eduard Cabré et al.. World J Gastroenterol. 2012. Impact of environmental and dietary factors on the course of inflammatory bowel disease. doi:10.3748/wjg.v18.i29.3814 PubMed
- [20] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [21] Alycia Leiby et al.. Pediatr Rev. 2012. Complementary, holistic, and integrative medicine: Crohn disease. doi:10.1542/pir.33-2-83 PubMed
- [22] Jason K Hou et al.. Am J Gastroenterol. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. doi:10.1038/ajg.2011.44 PubMed
- [23] Dan Turner et al.. Inflamm Bowel Dis. 2011. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. doi:10.1002/ibd.21374 PubMed
- [24] Gerard E Mullin. Nutr Clin Pract. 2011. Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses. doi:10.1177/0884533611400087 PubMed
- [25] Dan Turner et al.. Cochrane Database Syst Rev. 2009. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub3 PubMed
- [26] A K Akobeng. Aliment Pharmacol Ther. 2008. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. doi:10.1111/j.1365-2036.2007.03536.x PubMed
- [27] Devendra K Amre et al.. Am J Gastroenterol. 2007. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. doi:10.1111/j.1572-0241.2007.01411.x PubMed
- [28] Aneta Aleksandra Nielsen et al.. Digestion. 2007. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin … doi:10.1159/000101560 PubMed
- [29] D Turner et al.. Cochrane Database Syst Rev. 2007. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. doi:10.1002/14651858.CD006320.pub2 PubMed
- [30] Angie Macdonald. Gastroenterol Nurs. 2006. Omega-3 fatty acids as adjunctive therapy in Crohns disease. doi:10.1097/00001610-200607000-00005 PubMed
- [31] C Romano et al.. World J Gastroenterol. 2005. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, … doi:10.3748/wjg.v11.i45.7118 PubMed
- [32] A A Nielsen et al.. Aliment Pharmacol Ther. 2005. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. doi:10.1111/j.1365-2036.2005.02698.x PubMed
- [33] Robert F Grimble. Curr Opin Gastroenterol. 2005. Immunonutrition. doi:10.1097/01.mog.0000153360.90653.82 PubMed
- [34] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
- [35] Artemis P Simopoulos. J Am Coll Nutr. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. doi:10.1080/07315724.2002.10719248 PubMed
- [36] Khursheed N Jeejeebhoy. Curr Opin Gastroenterol. 2002. Enteral feeding. doi:10.1097/00001574-200203000-00010 PubMed
- [37] Khursheed N Jeejeebhoy. Curr Opin Clin Nutr Metab Care. 2002. Enteral feeding. doi:10.1097/00075197-200211000-00013 PubMed
- [38] D Schwab et al.. Z Gastroenterol. 1998. [Enteral nutrition in acute Crohn disease]. PubMed
- [39] H Lorenz-Meyer et al.. Scand J Gastroenterol. 1996. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study … doi:10.3109/00365529609010352 PubMed
- [40] C Cukier et al.. Arq Gastroenterol. 1996. [Biological activity of fish oil]. PubMed
- [41] J Vilaseca et al.. Gut. 1990. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. doi:10.1136/gut.31.5.539 PubMed
FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।